Martingale Asset Management L P Has $606,000 Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Martingale Asset Management L P raised its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 36.9% in the third quarter, Holdings Channel.com reports. The fund owned 37,923 shares of the company’s stock after acquiring an additional 10,226 shares during the quarter. Martingale Asset Management L P’s holdings in Entrada Therapeutics were worth $606,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in TRDA. Vanguard Group Inc. lifted its stake in shares of Entrada Therapeutics by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock valued at $15,288,000 after purchasing an additional 13,742 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Entrada Therapeutics by 13.4% in the second quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company’s stock worth $1,787,000 after buying an additional 14,838 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Entrada Therapeutics by 87.2% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 27,631 shares of the company’s stock worth $394,000 after acquiring an additional 12,868 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Entrada Therapeutics by 25.3% during the 2nd quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock valued at $526,000 after acquiring an additional 7,452 shares during the last quarter. Finally, Acadian Asset Management LLC raised its stake in shares of Entrada Therapeutics by 135.1% in the 2nd quarter. Acadian Asset Management LLC now owns 13,367 shares of the company’s stock valued at $190,000 after acquiring an additional 7,682 shares in the last quarter. 86.39% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on TRDA shares. Oppenheimer upped their target price on Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 6th. HC Wainwright upped their price objective on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th.

Insiders Place Their Bets

In other Entrada Therapeutics news, CFO Kory James Wentworth sold 3,195 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $14.97, for a total value of $47,829.15. Following the completion of the sale, the chief financial officer now owns 76,486 shares in the company, valued at approximately $1,144,995.42. This trade represents a 4.01 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Nathan J. Dowden sold 1,904 shares of Entrada Therapeutics stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $15.07, for a total value of $28,693.28. Following the sale, the chief operating officer now directly owns 125,996 shares in the company, valued at $1,898,759.72. The trade was a 1.49 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,933 shares of company stock valued at $530,786 in the last three months. Company insiders own 7.59% of the company’s stock.

Entrada Therapeutics Stock Performance

NASDAQ TRDA opened at $20.17 on Wednesday. The stock has a 50-day simple moving average of $17.80 and a 200 day simple moving average of $16.38. Entrada Therapeutics, Inc. has a twelve month low of $11.35 and a twelve month high of $20.50. The stock has a market capitalization of $754.76 million, a PE ratio of 12.69 and a beta of -0.18.

Entrada Therapeutics Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.